You are here
Latest 9-Valent HPV Vaccine May Prevent 80% of Cervical Cancers
A recently approved 9-valent human papillomavirus (HPV) vaccine (Gardasil-9, Merck) can potentially prevent 80% of cervical cancers in the U.S. if given to all 11- or 12-year-old children before they are exposed to the virus, according to researchers at Cedars-Sinai Medical Center in Los Angeles, California.
In addition to protecting against 80% of cervical cancers, the 9-valent HPV vaccine, which includes seven cancer-causing HPV types (16, 18, 31, 33, 45, 52, and 58), has the potential to protect against nearly 19,000 other cancers diagnosed in the U.S., including anal, oropharyngeal, and penile cancers, the researchers say. This is a 13% increase in protection against HPV-related cancers in comparison with the first vaccines on the market, Gardasil (Merck) and Cervarix (GlaxoSmithKline), which protected against only HPV types 16 and 18.
The new findings come from a study published in the Journal of the National Cancer Institute. The Centers for Disease Control and Prevention initiated the research effort, in conjunction with Cedars-Sinai.
“This is the first comprehensive study of its kind and shows the potential not only to reduce the global cancer burden, but also to guide clinical decision-making with regard to childhood vaccinations,” said senior author Marc T. Goodman, PhD, MPH.
The study found that Gardasil-9 also has the potential to protect against an additional 8% of oropharyngeal cancers, which can involve the base of the tongue and the tonsils. This disease is the second most-common HPV-associated cancer.
Moreover, the 9-valent vaccine was also found to potentially increase protection from other HPV-related cancers, including those of the vulva (from 71% to 92%); the vagina (73% to 98%; the penis (76% to 90%); and the anus (87% to 96%).
To compile the data, the researchers examined 2,670 HPV DNA tissue samples from seven population-based cancer registries.
Source: EurekAlert; May11, 2015.